{"disease":{"id":"ada-scid","name":"ada scid"},"drugs":{"marketed":[{"drug_id":"elapegademase","indication_name":"Adenosine deaminase severe combined immune deficiency (ADA-SCID)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revcovi","generic_name":"ELAPEGADEMASE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Revcovi works by replacing the deficient enzyme adenosine deaminase, allowing the body to break down toxic substances."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00006319","title":"Molecular and Clinical Studies of Primary Immunodeficiency Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":266,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT01852071","title":"Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT03645460","title":"Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT01420627","title":"EZN-2279 in Patients With ADA-SCID","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Leadiant Biosciences, Inc.","has_results":true},{"nct_id":"NCT02022696","title":"Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT01182857","title":"Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}